189 related articles for article (PubMed ID: 31870123)
61. Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy.
De Sanctis JB; Charris J; Blanco Z; Ramírez H; Martínez GP; Mijares MR
Anticancer Agents Med Chem; 2023; 23(10):1122-1144. PubMed ID: 35598250
[TBL] [Abstract][Full Text] [Related]
62. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
[TBL] [Abstract][Full Text] [Related]
63. A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
Lim AM; Corry J; Collins M; Peters L; Hicks RJ; D'Costa I; Coleman A; Chua M; Solomon B; Rischin D
Oral Oncol; 2013 May; 49(5):468-74. PubMed ID: 23369852
[TBL] [Abstract][Full Text] [Related]
64. Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.
Wang S; Zhang H; Cheng L; Evans C; Pan CX
Anticancer Res; 2010 Nov; 30(11):4573-8. PubMed ID: 21115908
[TBL] [Abstract][Full Text] [Related]
65. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
Li X; Roife D; Kang Y; Dai B; Pratt M; Fleming JB
Oncogene; 2016 Sep; 35(37):4881-90. PubMed ID: 26876211
[TBL] [Abstract][Full Text] [Related]
66. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
[TBL] [Abstract][Full Text] [Related]
67. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
Bellmunt J; de Wit R; Albanell J; Baselga J
Eur J Cancer; 2001 Nov; 37(17):2212-5. PubMed ID: 11677109
[TBL] [Abstract][Full Text] [Related]
68. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
69. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
[TBL] [Abstract][Full Text] [Related]
70. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
[TBL] [Abstract][Full Text] [Related]
71. The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Xu R; Ji Z; Xu C; Zhu J
Medicine (Baltimore); 2018 Nov; 97(46):e12912. PubMed ID: 30431566
[TBL] [Abstract][Full Text] [Related]
72. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
[TBL] [Abstract][Full Text] [Related]
73. Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
Bridges BB; Thomas L; Hausner PF; Doyle LA; Bedor M; Smith R; Brahmer J; Edelman MJ
Lung Cancer; 2008 Jul; 61(1):61-6. PubMed ID: 18201795
[TBL] [Abstract][Full Text] [Related]
74. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K
Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976
[TBL] [Abstract][Full Text] [Related]
75. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Robert F; Blumenschein G; Herbst RS; Fossella FV; Tseng J; Saleh MN; Needle M
J Clin Oncol; 2005 Dec; 23(36):9089-96. PubMed ID: 16301597
[TBL] [Abstract][Full Text] [Related]
76. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
77. First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study.
Tay SK; Ilanchadran A; Tan TY
BJOG; 2006 Dec; 113(12):1388-92. PubMed ID: 17081186
[TBL] [Abstract][Full Text] [Related]
78. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
Obasaju CK; Ye Z; Bloss LP; Monberg MJ; Curiel RE
Clin Lung Cancer; 2005 Nov; 7(3):202-7. PubMed ID: 16354316
[TBL] [Abstract][Full Text] [Related]
79. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
Liu DM; Zhang XD; Yang L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
[TBL] [Abstract][Full Text] [Related]
80. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Chi KH; Ko HL; Yang KL; Lee CY; Chi MS; Kao SJ
Oncotarget; 2015 Jun; 6(18):16735-45. PubMed ID: 25944689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
